MD Anderson and Jazz Pharmaceuticals collaborate to investigate the potential of zanidatamab in HER2-expressing cancers

The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz’s investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.

Next-gen implants could be powered by dual-energy harvesting technology

Implantable biomedical devices -; like pacemakers, insulin pumps and neurostimulators -; are becoming smaller and utilizing wireless technology, but hurdles remain for powering the next-generation

February 24, 2024

Gates-backed study of faster tuberculosis drug treatments kicks off in South Africa

An important test of new drugs that aim to treat tuberculosis infections more efficiently has begun in South Africa. The Phase II clinical trial, sponsored

August 10, 2023

Fast Stroke Thrombolysis Boosts Impact of Thrombectomy

PHOENIX — Sooner is better for intravenous thrombolysis (IVT) given before mechanical thrombectomy for acute ischemic stroke, a meta-analysis of patient-level data from randomized controlled

February 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.